In an attempt to curb inaccurate patent listings in the Food and Drug Administration’s “Orange Book,” a list of drugs the FDA has deemed safe and effective, the Federal Trade Commission has sent warning letters and deemed more than 300 patents unsuitable.
The disputed patents include a junk patent for Ozempic, among other drugs for COPD, diabetes, weight loss, and asthma. Ozempic has been lauded for its weight-loss effects, though some have abused the drug.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.